Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis by Marthi, Amarnath et al.
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050929/?report=printable[9/10/2019 7:47:53 AM]
J Am Soc Nephrol. 2018 Jul; 29(7): 2015–2027.
Published online 2018 May 15.
doi: 10.1681/ASN.2017121334: 10.1681/ASN.2017121334
PMCID: PMC6050929
PMID: 29764921
Fibroblast Growth Factor-23 and Risks of Cardiovascular and
Noncardiovascular Diseases: A Meta-Analysis
Amarnath Marthi,  Killian Donovan,  Richard Haynes,  David C. Wheeler,  Colin Baigent,  Christopher M. Rooney,
Martin J. Landray,  Sharon M. Moe,  Jun Yang,  Lisa Holland,  Romina di Giuseppe,  Annet Bouma-de Krijger,
Borislava Mihaylova,  and William G. Herrington
Health Economics Research Centre,
Clinical Trial Service Unit and Epidemiological Studies Unit, and
Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of
Oxford, Oxford, UK;
Centre for Nephrology, University College London, London, UK;
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana;
Global Biostatistics Science, Amgen Inc., Thousand Oaks, California;
Institute of Epidemiology, Christian–Albrechts University of Kiel, Kiel, Germany;
Department of Nephrology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; and
Centre for Primary Care and Public Health, Queen Mary University of London, London, UK
Corresponding author.
A.M., K.D., B.M., and W.G.H. contributed equally to this work.
Correspondence: Dr. Borislava Mihaylova, Health Economics Research Centre, Nuffield Department of Population
Health, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. Email: boby.mihaylova@dph.ox.ac.uk
Received 2017 Dec 28; Accepted 2018 Mar 30.
Copyright © 2018 by the American Society of Nephrology
Abstract
Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in the increased
risk of cardiovascular disease in patients with CKD.
Methods We identified prospective studies reporting associations between FGF-23 concentration and risk
of cardiovascular events. Maximally adjusted risk ratios (RRs) were extracted for each outcome and scaled
to a comparison of the top versus bottom third of the baseline FGF-23 concentration, and the results
aggregated.
Results Depending on the assay used, median FGF-23 concentrations were 43–74 RU/ml and 38–47 pg/ml
in 17 general population cohorts; 102–392 RU/ml in nine cohorts of patients with CKD not requiring
dialysis; and 79–4212 RU/ml and 2526–5555 pg/ml in eight cohorts of patients on dialysis. Overall,
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comparing participants in the top and bottom FGF-23 concentration thirds, the summary RRs (95%
confidence intervals [95% CIs]) were 1.33 (1.12 to 1.58) for myocardial infarction, 1.26 (1.13 to 1.41) for
stroke, 1.48 (1.29 to 1.69) for heart failure, 1.42 (1.27 to 1.60) for cardiovascular mortality, and 1.70 (1.52
to 1.91) for all-cause mortality. The summary RR for noncardiovascular mortality, calculated indirectly, was
1.52 (95% CI, 1.28 to 1.79). When studies were ordered by average differences in FGF-23 concentration
between the top and bottom thirds, there was no trend in RRs across the studies.
Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular
(atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any
exposure–response relationship, suggest that the relationship between FGF-23 and cardiovascular disease
risk may be noncausal.
Keywords: cardiovascular disease, chronic kidney disease, dialysis, fibroblast, heart failure, FGF23
Abstract
Cardiovascular disease risk increases as kidney function declines and this elevated risk is apparent even in
early CKD.  Cardiovascular disease in people with CKD is characterized particularly by arterial stiffening
and left ventricular hypertrophy, which becomes increasingly marked as CKD progresses.  People with
CKD are also at increased risk of atherosclerotic heart disease. It has been suggested that some of the excess
cardiovascular risk in CKD may be mediated through disordered calcium-phosphate metabolism due to
reduced kidney function. 
Blood fibroblast growth factor-23 (FGF-23) concentration rises early in CKD, and increases exponentially
in relation to eGFR, functioning to maintain phosphate homeostasis as the capacity for urinary phosphate
excretion declines.  FGF-23 possesses an atypical heparin-binding domain, which results in a low binding
affinity to most FGF receptors.  Its physiologic actions may therefore be limited to the parathyroid glands
and kidney, where the coreceptor Klotho is abundantly expressed. In the kidney, FGF-23 downregulates
renal proximal tubular sodium-phosphate cotransport function, enhancing urinary phosphate excretion, and
reduces vitamin D 1-α hydroxylation, leading to less intestinal calcium and phosphate absorption.
However, FGF-23 could have Klotho-independent actions in other tissues, including the heart,  and may
contribute to the etiology of structural heart disease in patients with CKD.  If so, interventions targeting
FGF-23 might hold therapeutic potential.
We conducted a systematic review and meta-analysis of the evidence from prospective studies for
associations between FGF-23 and the risk of different cardiovascular diseases. We compared the evidence
for associations among cohorts of people unselected for CKD (general population cohorts) with those in
patients with CKD who were not receiving dialysis at the time of recruitment (nondialyzed CKD cohorts)
and in patients on dialysis. We assessed for evidence of an exposure–response relationship both within and
across each of these three separate populations.
Methods
Search Strategy/Selection Strategy
A systematic and comprehensive search for English language publications with mention of FGF-23 or
equivalent terms was performed in MEDLINE (1948–April 2017) and EMBASE (1974–April 2017, see
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Supplemental Table 1 for terms). Abstracts were reviewed and cohort studies in adults were selected for
inclusion in the meta-analysis if (1) FGF-23 was a key exposure of interest, (2) at least one clinical
cardiovascular disease outcome was assessed, and (3) outcomes were ascertained prospectively.
Cardiovascular outcomes of interest included myocardial infarction, stroke, heart failure, and peripheral
arterial disease as well as mortality attributed to cardiovascular disease. Full texts of publications that
appeared to meet inclusion criteria were reviewed. Duplicate studies and those that included <200
participants were excluded. The quality of remaining studies was assessed using the Newcastle–Ottawa
scale,  and studies excluded if their results were at moderate-to-high risk of bias (score of <6/9). A study of
terminal heart failure was excluded post hoc as the population was at exceedingly high risk.
Data Extraction
Three authors (A.M., K.D., and C.M.R.) extracted the following data from full-text articles: study and study
population characteristics, FGF-23 assay type (C-terminal, reported in relative units per milliliter [RU/mL],
or intact, reported in picograms per milliliter [pg/mL]), measures of FGF-23 distribution, details of
statistical models, covariates used for multivariate adjustments, follow-up duration, and hazard ratios/risk
ratios (RRs) for relevant cardiovascular outcomes for all reported models and, where reported, all-cause and
cardiovascular mortality. Where necessary, further data were requested from study investigators.
Statistical Analyses
To assess the FGF-23 associations across the wide range of FGF-23 concentrations encountered in different
populations, meta-analysis was prespecified to be performed overall and within three study population
types: (1) general population (unselected individuals), (2) patients with nondialyzed CKD (defined as an
eGFR<60 ml/min per 1.73 m ), and (3) patients on dialysis.
For each study, we aimed to extract from the primary publication, for each outcome, the hazard ratio or RR
yielded by the model that included the greatest number of covariates. These covariates included
incrementally: basic demographics (+); cardiovascular risk factors including diabetes, body mass index, and
smoking (++); kidney function (+++); and markers of CKD–mineral bone disorder (++++). Because of the
usually skewed nature of FGF-23 distributions, studies reported associations for top versus bottom quintile,
quartile, or third of the FGF-23 distribution, or less frequently, per SD or a unit increase in log-transformed
FGF-23. To enable comparisons and synthesis of data across the studies, these associations were converted
(where necessary) to a measure of association corresponding to the top versus bottom third of the baseline
FGF-23 concentration using established methods (see Supplemental Methods, Supplemental Table 2 for
more detail).  Where noncardiovascular mortality was not reported, RRs were derived indirectly from
cardiovascular and all-cause mortality results assuming that on the natural logarithm scale, the RR for all-
cause mortality is an inverse-variance weighted average of the RRs for cardiovascular and
noncardiovascular mortality.
The heterogeneity between studies (both within each population and overall) was summarized. Random-
effects meta-analytical methods  were used to combine the RRs for the top versus bottom third of baseline
FGF-23 concentration in each study, yielding a summary RR for all studies.
As the median baseline FGF-23 concentration correlated strongly with interquartile range, standard tests for
linear trend (on a log scale) across studies ordered by median (or, if not reported, mean) baseline FGF-23
concentration (within each population and across all the individual studies) were used to assess whether
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larger absolute differences in FGF-23 concentration between top and bottom third were associated with
larger RRs. Trend tests were also performed across population-specific summary RRs after meta-analysis of
RRs from the contributing studies. In sensitivity analyses, to allow for a potentially different relationship in
dialysis patients, the trend tests across individual studies were repeated after excluding dialysis population
studies.
Primary analyses of disease associations did not take account of whether studies used C-terminal or intact
assays, which is equivalent to the assumption that the results between the two assays are approximately
comparable. However, this assumption may not necessarily hold as, for example, intraperson biologic
variability of intact FGF-23 may be higher than C-terminal FGF-23.  To investigate the sensitivity of
results to this assumption, analyses were performed repeating trend tests, firstly after converting intact FGF-
23 concentration to an approximately equivalent C-terminal concentration using the formula intact FGF-
23=0.110×C-terminal FGF-23+32.2, developed from a small healthy general population,  and secondly,
after excluding all studies that only reported intact FGF-23. To further assess whether associations in
individual studies could have been affected by within-person FGF-23 variability, regression dilution ratios
were calculated from individual studies that had repeat FGF-23 measurements,  using the McMahon
nonparametric quintile method.  RRs for cardiovascular and noncardiovascular outcomes were compared
by heterogeneity tests.  Analyses were performed using R version 3.2.1 (www.R-project.org) with the
“metafor” package v1.
Results
Our literature search (Supplemental Table 1) identified 2477 abstracts, of which 45 met the inclusion criteria
(Figure 1). Three studies were excluded after a standard assessment for bias (Supplemental Table 3).
Eight studies reported associations that could not be extracted or reliably expressed as RRs comparing the
top versus bottom third of baseline FGF-23 concentration (see Supplemental Table 4 for results from these
and the other excluded studies).  Of 34 studies included in primary analyses, 17 were in predominantly
general population cohorts,  nine were in patients with CKD not on dialysis,  and eight in
patients on dialysis  (Figure 1). For patients on dialysis, a single large trial (EValuation Of Cinacalcet
HCl Therapy to Lower CardioVascular Events [EVOLVE], n=2985) provided all the data on myocardial
infarction, stroke, and heart failure (outcomes that were all confirmed by clinician adjudicators).
Table 1 describes the characteristics of included studies. Most of the studies (26 out of 34) measured FGF-
23 concentrations using a C-terminal assay, with the remainder (eight out of 34) using an intact assay.
Measures (median or, if unavailable, mean) of FGF-23 concentration were lowest in general population
cohorts (43–74 RU/ml and 38–47 pg/ml for the respective assays); higher in nondialyzed CKD cohorts
(102–392 RU/ml), and substantially higher in dialysis cohorts (79–4212 RU/ml and 2526–5555 pg/ml; 
Table 1).
Across these three populations, the estimated absolute difference in mean FGF-23 concentrations between
the top and the bottom third of the FGF-23 distributions ranged from 72 RU/ml in general population
studies, to 433 RU/ml in nondialyzed CKD studies, to 8644 RU/ml in dialysis population studies (C-
terminal studies only).
It was notable that the ten general population cohorts had a mean age of 65 years or above (Table 1). The
estimated crude mortality rates were, on average, high in all populations, with evidence of higher mortality
with reduced kidney function. For example, the average all-cause mortality ranged from 1.9% to 5.3% per
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annum (p.a.) across the general populations, 2.0% to 14.2% p.a. in nondialyzed CKD populations, and 2.0%
to 21.0% p.a. in dialysis populations.
Association between FGF-23 and Risk of Cardiovascular Events
Six studies assessed the association between FGF-23 and risk of myocardial infarction (three in general
populations,  two in patients with CKD not on dialysis,  and one in patients on dialysis ). Overall,
comparing participants in the top versus bottom third of baseline FGF-23 concentration, there was a 33%
increased risk of myocardial infarction (summary RR, 1.33; 95% confidence interval [95% CI], 1.12 to
1.58), but no evidence of linear trend across the different populations studied (trend P=0.32; Figure 2).
For the studies reporting an interquartile range of baseline FGF-23 concentrations, there was good
correlation between median baseline FGF-23 concentration and the interquartile range (correlation
coefficient, 0.99), so ordering studies by increasing baseline FGF-23 concentration effectively orders the
studies by increasing absolute difference between the means of FGF-23 concentrations in the top versus
bottom third of each study’s FGF-23 distribution. Tests for linear trend in the RRs for myocardial infarction
across the ordered studies were nonsignificant both within the three separate populations and across all
individual studies (trend across all individual studies P=0.22; Supplemental Figure 1).
Associations between FGF-23 and risk of stroke of any type were reported in nine studies, including six in
general populations,  two in nondialyzed CKD populations,  and one in dialysis
populations.  Overall, comparing those in the top versus the bottom third of baseline FGF-23 concentration,
there was a 26% increased risk of stroke (RR, 1.26; 95% CI, 1.13 to 1.41). This increase in risk was
consistent between populations (trend P=0.17; Figure 2), and there was no significant trend toward larger
RRs with higher median FGF-23 difference both within each population considered separately (where
relevant) and across all studies (trend across all individual studies P=0.95; Supplemental Figure 2).
Four general population studies (n=1251 events)  and a small nondialyzed CKD study (n=43
events)  reported ischemic stroke events. Overall, no significant association between FGF-23 and risk of
ischemic stroke was observed for the top versus the bottom third of baseline FGF concentration (RR, 1.08;
95% CI, 0.92 to 1.27; Supplemental Figure 3).
Associations between FGF-23 and risk of heart failure were reported in ten studies, including five in a
general population,  four in patients with nondialyzed CKD,  and one in patients on
dialysis.  Overall, comparing patients in the top versus the bottom third of baseline FGF-23 concentration,
there was a 48% increased risk of heart failure (RR, 1.48; 95% CI, 1.29 to 1.69). There was no evidence of
trend across populations (trend P=0.89; Figure 2) and no clear trend toward larger RRs with higher median
FGF-23 difference both within each population considered separately and overall (trend across all individual
studies P=0.76; Supplemental Figure 4). There was also no good evidence that FGF-23 was more strongly
associated with heart failure than myocardial infarction or stroke, overall (heterogeneity P=0.23) or in any
of the three separate populations (Figure 2).
Associations between FGF-23 and risk of peripheral artery disease and some other noted cardiovascular
outcomes are provided in Supplemental Table 5.
Association between FGF-23 and Mortality
Twenty-three studies reported associations between FGF-23 and all-cause mortality: seven in a general
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population,  eight in a nondialyzed CKD population,  and eight in a dialysis
population.  Overall, comparing participants in the top versus bottom third of baseline FGF-23
concentration, there was an increased risk of death from all causes (RR, 1.70; 95% CI, 1.52 to 1.91). There
was no good evidence of a trend across the three populations (trend P=0.76; Figure 3) or toward larger RRs
with higher median FGF-23 at baseline (trend across all individual studies P=0.97; Supplemental Figure 5).
Eleven studies reported associations between FGF-23 level and cardiovascular mortality (seven studies in
general populations,  two in nondialyzed CKD populations,  and two in dialysis
populations ). Overall, comparing patients in the top versus bottom third of the baseline FGF-23
concentration, there was a 42% increased risk of cardiovascular mortality (RR, 1.42; 95% CI, 1.27 to 1.60)
with no evidence of trend across populations (trend P=0.53; Figure 3) and no trend toward larger RRs with
higher median FGF-23 (trend across all individual studies P=0.49; Supplemental Figure 6).
Among patients on dialysis in the EVOLVE trial,  comparing patients in the top versus the bottom third of
the baseline FGF-23 concentration, there was a 27% (RR, 1.27; 95% CI, 1.02 to 1.58) increased risk of
noncardiovascular mortality (n=514 deaths), which was similar to the RR for cardiovascular mortality (RR,
1.26; 95% CI, 1.00 to 1.57; n=607 deaths). Only one of the other nine studies (a general population cohort)
reported RRs for cardiovascular mortality (RR, 1.76; 95% CI, 1.34 to 2.32; n=474) as well as for
noncardiovascular mortality (RR, 1.47; 95% CI, 1.17 to 1.85; n=612 deaths).  For the remaining eight
studies, RRs for noncardiovascular mortality were derived indirectly, using associations for cardiovascular
and all-cause mortality.  The overall combined RR for all studies for noncardiovascular
mortality for the top versus the bottom third of the baseline FGF-23 concentration was 1.52 (95% CI, 1.28
to 1.79), with results suggesting that for each of the separate populations, the RRs for cardiovascular and
noncardiovascular mortality were comparable (Figure 4).
Sensitivity Analyses and Assessment for Publication Bias
The results of trend tests remained nonsignificant after exclusion of studies on patients on dialysis
(Supplemental Figures 1, 2, and 4– 6), after exclusion of studies that only reported intact FGF-23
concentrations, and after using a formula for interassay conversion.  Repeat measurements within groups of
FGF-23 were highly correlated in all three types of populations studied (regression dilution ratios all >0.8,
Supplemental Table 6),  so adjustment for regression-dilution bias was not performed. All-cause and
cardiovascular mortality associations were not substantially affected by adjustment for other markers of
CKD–mineral bone disorder (Supplemental Figure 7).
Funnel plots of associations between FGF-23 and all-cause mortality by type of population suggested
evidence for publication bias for the general population cohorts (Egger regression test P=0.005) and that
RRs for all-cause mortality may be slight overestimates (Supplemental Figures 5 and 8). There was no
important heterogeneity between studies with respect to other outcomes (Supplemental Figures 1– 4 and 6).
Discussion
This systematic review and meta-analysis assessed the epidemiologic associations between FGF-23
concentration and cardiovascular outcomes, as well as associations with cardiovascular and all-cause
mortality in populations with and without known kidney disease. Overall, we found that, irrespective of a
population’s level of kidney function, a difference in FGF-23 concentration corresponding to that between
top and bottom thirds of baseline FGF-23 concentration was associated with about 30% increased risk of
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myocardial infarction and stroke, 40% increased risk of cardiovascular mortality, and 50% increased risk of
heart failure. In the studies where it was possible to estimated effects on both cardiovascular and
noncardiovascular mortality, we found that the strength of the association between FGF-23 and these
categories of deaths was approximately similar.
The Bradford Hill criteria for causality of a disease risk factor includes the presence of epidemiologic
associations that are both consistent and specific for that disease, evidence of a biologic gradient (i.e.,
greater exposure leads to increased effect, which we refer to as exposure-response), temporality (i.e., the
cause precedes the effect), and biologic plausibility.
In support of raised FGF-23 concentration being a cause of cardiovascular disease, our study found
consistent moderate associations between FGF-23 and disease risks. FGF-23 concentration also rises before
any other marker of CKD–mineral bone disorder,  so it temporally mirrors the rise in cardiovascular risk as
CKD progresses.  In addition, there is biologic plausibility because cardiac myocytes exposed to FGF-23
become hypertrophied and develop electrophysiologic disturbances (sometimes referred to as “off-target”
effects as they appear to be Klotho-independent).
We also observed that FGF-23 was strongly associated with noncardiovascular causes of death, reflecting a
lack of specificity of the associations between raised FGF-23 concentration and disease risk. This
observation could reflect the pleiotropy of FGF-23 in disease causation. It has previously been reported that
raised FGF-23 concentration is associated with a higher risk of ESRD,  AKI (RR for top versus bottom
quartile, 1.99; 95% CI, 1.04 to 3.80),  fractures (RR, 1.56; 95% CI, 1.11 to 2.20),  and serious infection
(RR, 1.59; 95% CI, 1.14 to 2.22).  There is emerging evidence that FGF-23 may promote inflammation
through direct effects on hepatocytes,  and predispose to infection through downregulation of monocytic
expression of 1,25 dihydroxycholecalciferol  or other effects.  A mechanistic study has also suggested that
FGF-23 may promote progression of prostate cancer.
An alternative, more plausible explanation for the observed nonspecificity of associations across a range of
disease outcomes is residual confounding. This may arise because of imprecise or incomplete measurement
of baseline prognostic factors other than FGF-23. Examples of such factors include level of kidney function
(which is measured with greater error at high eGFR), duration of CKD, and risk factors that correlate with
low kidney function.
Furthermore, we found no evidence for a log-linear exposure-response relationship such as that which is
commonly observed for known causes of cardiovascular disease (e.g., LDL cholesterol  and BP ).
Indeed, the RRs corresponding to a difference between top and bottom thirds of FGF-23 distribution were of
similar magnitude in each of the three populations despite the absolute difference in FGF-23 varying by two
orders of magnitude across these populations. Such a pattern could potentially be explained by a “log-log”
relationship with flattening of the exposure-response curve at high FGF-23 concentration. But this shape of
association would imply that, if FGF-23 is a cause of cardiovascular disease, therapeutic agents designed to
reduce FGF-23 would need to achieve large absolute reductions in FGF-23 in those with high levels to
achieve worthwhile risk reductions.
A limitation of this meta-analysis is that we were, for the most part, restricted to published summary data.
The availability of individual participant-level data from all eligible studies could allow for more granular
estimation of associations and perhaps a more sensitive analysis of any exposure-response relationship using
a standardized method with fewer assumptions. It would also allow for the inclusion of the studies that
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could not be reliably converted onto a top versus bottom third scale. However, the studies excluded because
of inability to convert associations showed positive associations between FGF-23 and disease risks that were
similar in size to those observed by the included studies (Supplemental Table 4).  Furthermore, given the
lack of trends across the three population types despite a two-fold increase in the absolute difference in
FGF-23 concentration, it is unlikely that individual participant data would identify an important log-linear
trend missed by our tabular meta-analysis. Individual participant-level data would also not overcome
residual confounding, which is the main limitation of this meta-analysis. Finally, not all relevant studies
reported associations for all outcomes of interest (which may have introduced bias) and there was a lack of
detailed data on noncardiovascular causes of death, so it was not possible to examine whether there were
deaths (e.g., from cancer) that were particularly strongly associated with FGF-23.
In summary, this systematic review and meta-analysis has demonstrated that across a wide range of levels of
kidney function, higher FGF-23 concentration was consistently associated with modest increased risks of
myocardial infarction, heart failure, stroke, and cardiovascular death. However, higher FGF-23 was also
associated with an increased risk of noncardiovascular causes of death. Our findings suggest that
associations between FGF-23 and particular diseases, both in populations with CKD and those without
known disease, may not signify cause and effect.
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Publication
Author, Study
Acronym
Study
Location
No. of
Participants;Follow-
Up Duration
Baseline
Demographics
Baseline
Comorbidity
Prevalences
FGF-23
Assay
Type
Average
FGF-23
Concentration
General population studies
Ärnlöv et al.,
ULSAM
Uppsala,
Sweden
727; Median: 9.7 yr
(range, 0.3–12.9)
Age: 78 yr DM: 13% Intact Median 44
pg/ml (range,
9–162)
Men: 100% eGFR: 74
(17)
CVD: 27%
Ärnlöv et al.,
PIVUS
Uppsala,
Sweden
1003; Median: 5.1
yr (range, 4.8–5.8)
Age: 70 yr DM: 12% Intact Mean 47
pg/ml (SD
24)
Men: 50% eGFR: 80
(14)
White: 100% CVD: 16%
Brandenburg et
al.,  LURIC
Germany 2974; Median: 9.9
yr
Age: 63 (10)
yr
DM: 40% C-terminal Median 54
RU/ml (IQR,
40–78)Men: 69% eGFR<60:
14%
White: 100% CAD: 78%
Deo et al.,
CHS
USA 3244; Mean: 8.1 yr
(SD 3.2)
Age: 78 (5) yr DM: 15% C-terminal Median 70
RU/ml (IQR,
53–99)
Men: 40% eGFR: 71
(19)
Black: 16% HF: 9% MI:
11%
di Giuseppe et
al.,  EPIC-
Potsdam
Germany 1443; Mean 8 yr
(SD 2.2)
Age: 52 DM: 7% C-terminal Median 48
RU/ml (IQR,
NR)
Men: 44% eGFR: NR
White: NR CAD: 10.8%
di Giuseppe et
al.,  EPIC-
Germany
Germany 2908; Mean: 8.2 yr Age: 52 DM: 6% C-terminal Median 54
RU/ml (IQR,
38–72)
Men: 50% eGFR: 108
White: NR Excluded MI
and ST
Garimella et
al.,  CHS
USA 3143; Median: 9.8
yr
Age: NR DM: NR C-terminal Median 71
RU/ml (IQR,
54–100)
Men: NR eGFR: NR
White: NR CVD: NR
Ix et al.,  CHS USA 3107; Median: 10.5
yr (IQR, 5.9–11.5)
Age: 78 (5) yr DM: 15% C-terminal Median 70
RU/ml (IQR,
53–99)
Men: 40% eGFR: 71
(19)
Black: 16% CVD: 29%
HF: 9%
Kestenbaum et
al.,  MESA
USA 6547; Median: 8.5
yr (IQR, 7.7–8.6)
Age: 62 yr DM: 12% Intact Median 38
pg/ml (IQR,
31–46)
Men: 47% eGFR: 84
(eGFR<60:
39
38
40
41
42
22
a
43
44
45
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16%) Mean: 40
pg/ml (SD
15)
White: 39% CVD: 0%
Lutsey et al.,
ARIC
USA 11,638; Median:
18.6 yr (maximum,
20.9)
Age: 57 yr DM: 13% Intact Mean 44
pg/ml (SD
16)
Men: 43% eGFR: 92
(eGFR<60:
3%)
Black: 25% CVD: 0%
Masson et al.,
PREDICTOR
Lazio, Italy 1835; Mean: 3.8 yr Age: 73 (5) yr DM: 17% C-terminal Median 74
RU/ml (IQR,
58–97)
Men: 53% Creatinine:
1.0 (0.3)
mg/dl
White: NR CVD: 29%
Panwar et al.,
REGARDS
USA 1551 (615 cases);
Follow-up: NR
Age: 65 yr DM: 21% C-terminal Median 70.5
RU/ml (IQR,
53–100)
Men: 45% eGFR: 86.5
Black: 40% CVD: 16%
Parker et al.,
HSS
San-
Francisco,
USA
833; Median: 6.0 yr Age: 67 (11)
yr
DM: 27% C-terminal Median 43
RU/ml (IQR,
29–72)Men: 81% eGFR<60:
22%
White: 60% CVD: 100%
Souma et al.,
NOMAS
USA 2525; Median: 14 yr Age: 69 (10)
yr
DM: 21% C-terminal Median 57
RU/ml (IQR,
44–81)Men: 36% eGFR: 80
(22)
White: 21% CVD: NR (no
STs)
Speer et al. Saarland,
Germany
859; Median: 2.3 yr
(IQR, 0.98–2.93)
Age: 64 yr DM: 25% C-terminal Median 65
RU/ml (IQR,
45–115)
Men: 69% Creatinine:
1.2 mg/dl (SD
0.8)
White: NR CAD: 43%
HF: 86%
Westerberg et
al.,  MrOS
Sweden 2838; Mean: 4.5 yr Age: 75.5 (3)
yr
DM: 9% Intact Median 44
pg/ml (IQR,
32–58)Men: 100% eGFR: 72
(20)
White: NR CVD: 19%
Wright et al.,
NOMAS
USA 2525; Mean: 12 yr
(SD 5)
Age: 69 (10)
yr
On glycemic
agents: 15%
C-terminal Median 57
RU/ml (IQR,
44–81)
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Men: 36% eGFR: 80
(22)
White: 21% CVD: NR (no
STs)
Nondialyzed CKD population studies
Alderson et
al.,  CRISIS
Salford, UK 463; Median: 3.8 yr
(IQR, 1.8–5.8)
Age: 64 (14)
yr
DM: 31% C-terminal Median 209
RU/ml (IQR,
128–470)Men: 62% eGFR: 29
(15)
White: 96% CVD: 29%
HF: 18%
Baia et al. Groningen,
The
Netherlands
593; Median: 7.0 yr
(IQR, 6.2–7.5)
Age: 52 (12)
yr
DM: 18% C-terminal Median 140
RU/ml (IQR,
95–219)Men: 54% eGFR: 47
(16)
White: 95% CVD: NR
Bouma-de
Krijger et al.,
MASTERPLAN
The
Netherlands
439; Follow-up: 2
yr
Age: 62 (12)
yr
DM: 23% C-terminal Median 149
RU/ml (IQR,
87–241)Men: 71% eGFR: 36
(15)
White: 93% CVD: 27%
Isakova et al.,
CRIC
USA 3879; 3.5 yr (IQR,
2.5–4.4)
Age: 58 (11)
yr
DM: 48% C-terminal Median 146
RU/ml (IQR,
96–239)Men: 55% eGFR: 43
(14)
Black: 42% CAD: 22%
HF: 10%
Kendrick et
al.,  HOST
USA 1099; Median: 2.9
yr
Mean: 2.8 yr (SD
1.1)
Age: 69 (11)
yr
DM: 55% C-terminal Median 392
RU/ml (IQR,
216–945)Men: 98% eGFR: 18 (6)
Black: 26% CVD: 57%
Levin et al.,
CanPREDDICT
Canada 2402; Median: 1 yr Age: 68 (13)
yr
DM: 48% C-terminal Median 237
RU/ml (IQR,
150–432)Men: 63% eGFR: 28 (9)
White: 89% CVD: NR
Munoz-
Mendoza et
al.,  CRIC
USA 3875; Median: 6.9
yr (IQR, 4.2–8.2)
Age: 58 yr DM: 48% C-terminal Median 146
RU/ml (IQR,
96–239)
Men: 55% eGFR: 44
(15)
Black: 42% CAD: 22%
HF: 10%
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Scialla et al.,
CRIC
USA 3860; Median: 3.7
yr (IQR, 2.5–4.7)
Age: 58 (11)
yr
DM: 49% C-terminal Median 146
RU/ml (IQR,
96–239)Men: 55% eGFR: 44
(15)
White: 42% CVD: 31%
Black: 41%
Seiler et al.,
CARE FOR
HOME
Hamburg,
Germany
444; Median: 2.6 yr
(IQR, 1.4–3.6)
Age: 65 (12)
yr
DM: 38% C-terminal Median 102
RU/ml (IQR,
64–164)Men: 60% eGFR: 45
(16)
White: NR Prevalent
CVD: 30%
Dialysis population studies
Chonchol et
al.,  HEMO
USA 1340; Mean: 2.8 yr
(SD 1.7)
Age: 57 (14)
yr
Hemodialysis:
100%
Intact Median 3118
pg/ml (IQR,
726–12,928)Men: 45% DM: 44%
Black: 64% CVD: 79%
Jean et al. France 219; Median: 1.9 yr Age: 67 (14)
yr
Hemodialysis:
100%
C-terminal Median 2740
RU/ml (IQR,
1192–8667)
Mean: 7060
(SD 13,500)
Men: 57% DM: 35%
White: NR CAD: 19%
Kim et al. South Korea 205; Mean: 3.5 yr Age: 47 (14)
yr
PD: 100% C-terminal Median 79
RU/ml (IQR,
34–155)Men: 60% DM: 31%
White: NR CAD: 7% HF:
8%
Moe et al.,
EVOLVE
International 2985; Median: 4.2
yr (IQR, 1.0–5.0)
Age: 54 yr Hemodialysis:
100%
Intact
(Millipore)
Median 5555
pg/ml (Q10–
Q90, 580–
19540)
Men: 59% DM: 32%
White: 58% CVD: 95%
HF: 23%
Montford et
al.,  HOST
USA 654; Median: 2.9 yr Age: 60 (11)
yr
Hemodialysis:
100%
C-terminal Median 4212
RU/ml (IQR,
1411–13,816)Men: 98% DM: 41%
White: 38% CVD: 52%
Nowak et al. Germany 239; Median: 2.5 yr
(IQR, 2.0–2.7)
Age: 68 (14)
yr
Hemodialysis:
100%
C-terminal Mean 883
RU/ml (SD
1940)Men: 64% DM: 38%
White: NR CAD: 31%
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Olauson et al. Sweden 229; Median: 1.9 yr
(range, 0.1–5)
Age: 55 yr Hemodialysis:
41%
Intact Median 2526
pg/ml (Q10–
Q90, 431–
19,495)
(IQR, 33–68) PD: 54%
Men: 65% DM: 34% (as
cause of
ESRD)
White: NR CVD: 41%
Scialla et al.,
CHOICE
USA 466; Median 3.4 yr
(IQR, 1.8–5.9)
Age: 58 (15)
yr
Hemodialysis:
100%
C-terminal Median 1577
RU/ml (IQR,
818–4946)Men: 55% DM: 57%
Black: 36% CVD: 56%
Open in a separate window
Age and eGFR are mean (SD). ULSAM, Uppsala Longitudinal Study of Adult Men; DM, diabetes mellitus; CVD,
cardiovascular disease; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors study; LURIC,
Ludwigshafen Risk and Cardiovascular Health study; IQR, interquartile range; CAD, coronary artery disease; CHS,
The Cardiovascular Health Study; HF, heart failure; MI, myocardial infarction; EPIC, European Prospective
Investigation into Cancer and Nutrition; NR, not reported; ST, stroke; MESA, Multi-Ethnic Study of
Atherosclerosis; ARIC, Atherosclerosis Risk in Communities Study; PREDICTOR, Valutazionedella PREvalenza
di DIsfunzione CardiacaasinTOmatica e di scompensocaRdiaco; REGARDS, Reasons for Geographic and Racial
Differences in Stroke; HSS, Heart and Soul Study; NOMAS, Stroke-free North Manhattan Study; MrOS,
multicenter prospective Osteoporotic Fractures in Men study; CRISIS, Chronic Renal Insufficiency Standards
Implementation Study; MASTERPLAN, Multifactorial approach and superior treatment efficacy in renal patients
with the aid of nurse practitioners; CRIC, Chronic Renal Insufficiency Cohort; HOST, Homocysteine in Kidney
and End Stage Renal Disease study; CanPREDDICT, Canadian study of prediction of death, dialysis and interim
cardiovascular events; CARE FOR HOME, Cardiovascular And REnal outcome in CKD stage 2–4 patients—The
FOuRth HOMburg evaluation; HEMO, The Hemodialysis Study; PD, peritoneal dialysis; EVOLVE, Evaluation of
Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events; Q10, 10th percentile; Q90, 90th percentile;
CHOICE, Choices for Healthy Outcomes in Caring for ESRD.
Approximated from median (IQR) of two mid quartiles.
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Association between FGF-23 and risk of cardiovascular disease event by population type. Heterogeneity tests across the
summary RRs for the three outcomes: all populations combined, P=0.23; general populations, P=0.59; nondialyzed CKD
populations, P=0.75; and dialysis populations, P=0.47.
Figure 3.
Association between FGF-23 and risk of all-cause and cardiovascular mortality by population type. *Number of events not
reported for one study.
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Association between FGF-23 concentration and risk of cause-specific mortality overall and by population type.
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